

Revision date: 04-Sep-2009

Version: 1.0

Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING 1.

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Ciprofloxacin Injection in 5% Dextrose

Trade Name:	Not applicable
Chemical Family:	Fluoroquinolone
Intended Use:	Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance:	Clear colorless to pale yellow solution
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term: Known Clinical Effects: EU Indication of danger:	Accidental ingestion may cause effects similar to those seen in clinical use. Quinolones may effect connective tissue structures. Tendonitis and tendon rupture have occurred as late as several months after quinolone treatment. The most common adverse reactions associated with the use of quinolones include gastrointestinal distress, such as nausea or diarrhea, and central nervous system (CNS) effects, including insomnia, dizziness, and seizures. Conlvusions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones. Not classified
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous				
Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Ciprofloxacin	85721-33-1	Not listed	Not Listed	1

Material Name: Ciprofloxacin Injection in 5% Dextrose Revision date: 04-Sep-2009

3. COMPOSITION/INFORMATION ON INGREDIENTS				
Hydrochloric Acid	7647-01-0	231-595-7	C;R35 T;R23	**
Lactic acid	50-21-5	200-018-0	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*
Dextrose	14431-43-7	Not listed	Not Listed	*

Additional Information:

* Proprietary ** to adjust pH Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES	
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.	
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.	
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.	

Material Name: Ciprofloxacin Injection in 5% Dextrose Revision date: 04-Sep-2009

Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	
General Handling:	Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Hydrochloric Acid

ACGIH Ceiling Threshold Limit: Australia PEAK	2 ppm 5 ppm 7 5 mm/m3
Austria OEL - MAKs	7.5 mg/m³ Listed
Belgium OEL - TWA	Listed
Bulgaria OEL - TWA	Listed
Cyprus OEL - TWA	Listed
	Listed
Czech Republic OEL - TWA	
Estonia OEL - TWA	Listed
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm MAK
	3.0 mg/m³ MAK Listed
Greece OEL - TWA	
Hungary OEL - TWA	Listed
Ireland OEL - TWAs	Listed
Italy OEL - TWA	Listed
Japan - OELs - Ceilings	5 ppm
	7.5 mg/m ³
Latvia OEL - TWA	Listed
Lithuania OEL - TWA	Listed
Luxembourg OEL - TWA	Listed
Malta OEL - TWA	Listed
Netherlands OEL - TWA	Listed
Poland OEL - TWA	Listed
Romania OEL - TWA	Listed
Slovenia OEL - TWA	Listed
Spain OEL - TWA	Listed

Engineering Controls:	Engineering controls should be used as the primary means to control exposures.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental
Personal Protective Equipment:	legislation. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Material Name: Ciprofloxacin Injection in 5% Dextrose Revision date: 04-Sep-2009

8. EXPOSURE CONTROLS	PERSONAL PROTEC	ΓΙΟΝ	
Hands: Eyes: Skin: Respiratory protection:	Wear impervious gloves if skin contact is possible. Safety glasses or goggles Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.		
9. PHYSICAL AND CHEMIC	AL PROPERTIES		
Physical State: Molecular Formula:	Solution Mixture	Color: Molecular Weight:	No data available. Mixture
Solubility:	Soluble: Water		
10. STABILITY AND REACT Stability: Conditions to Avoid: Incompatible Materials:	Stable under normal con Fine particles (such as de As a precautionary meas	ditions of use. ust and mists) may fuel fires/explosions sure, keep away from strong oxidizers	
11. TOXICOLOGICAL INFOR	MATION		
General Information:	The information included ingredients.	in this section describes the potential h	azards of the individual
Acute Toxicity: (Species, Route, E	nd Point, Dose)		
Ciprofloxacin Rat Oral LD50 > 2000 mg/	kg		
Lactic acid Rat Oral LD50 3543 mg/kg Rabbit Dermal LD50 >2000 r Acute Toxicity Comments:) indicates that the toxicity endpoint bei	ng tested was not achievable

at the highest dose used in the test. Irritation / Sensitization: (Study Type, Species, Severity)

Lactic acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Moderate Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ciprofloxacin

Reproductive & Fertility	Rat O	ral 100 mg/kg/day	NOAEL	No effects at maximum dose
Reproductive & Fertility	Rabbit	Oral 35 mg/kg/day	LOAEL	Maternal Toxicity, Not Teratogenic

Lactic acid

Material Name: Ciprofloxacin Injection in 5% Dextrose Revision date: 04-Sep-2009 Page 5 of 6 Version: 1.0

Ciprofloxacin In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative In Vitro Cell Transformation Assay Hamster Negative In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Forward Mutation Assay Mouse Negative In Vivo Dominant Lethal Assay Mouse Negative Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Hydrochloric Acid IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.						
Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Ciprofloxacin In Vitro Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative In Vitro Cell Transformation Assay Hamster Negative In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Oronucleus Mouse Negative In Vivo Dominant Lethal Assay Mouse Negative Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Hydrochloric Acid IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.						
Ciprofloxacin In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative In Vitro Cell Transformation Assay Hamster Negative In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Forward Mutation Assay Mouse Negative In Vivo Dominant Lethal Assay Mouse Negative Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Hydrochloric Acid IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	Reproductive & Fertility Rat C	rai 6.25 mg/kg/day NOEL Fertility, Not teratogenic				
In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative In Vitro Cell Transformation Assay Hamster Negative In Vitro Forward Mutation Assay Mouse Lymphoma Positive In Vitro Dominant Lethal Assay Mouse Negative In Vivo Dominant Lethal Assay Mouse Negative Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Hydrochloric Acid IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	Genetic Toxicity: (Study Type, Cell Type/Organism, Result)					
Hydrochloric Acid IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	In Vitro Cell Transformation Assay In Vitro Forward Mutation Assay In Vivo Micronucleus Mouse	Hamster Negative Mouse Lymphoma Positive Negative				
IARC: Group 3 12. ECOLOGICAL INFORMATION Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.				
Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided. 13. DISPOSAL CONSIDERATIONS Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	Hydrochloric Acid IARC:	Group 3				
avoided. 13. DISPOSAL CONSIDERATIONS Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	12. ECOLOGICAL INFORM	ATION				
Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be				
specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	13. DISPOSAL CONSIDERATIONS					
	Disposal Procedures:	specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental				
14. TRANSPORT INFORMATION						

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:

Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

Material Name: Ciprofloxacin Injection in 5% Dextrose Revision date: 04-Sep-2009

15. REGULATORY INFORMATION

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0% de minimis concentration acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size
CERCLA/SARA Hazardous Substances	2270 kg final RQ
and their Reportable Quantities:	5000 lb final RQ
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb TPQ gas only
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	231-595-7
Lactic acid	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	200-018-0
Water for injection	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	231-791-2
Dextrose	
Australia (AICS):	Listed

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R35 - Causes severe burns. R25 - Toxic if swallowed. Data Sources:	Publicly available toxicity information. Safety data sheets for individual ingredients.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet